{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:48:16Z","timestamp":1761630496816},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,10,13]],"date-time":"2008-10-13T00:00:00Z","timestamp":1223856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2008,10,13]],"date-time":"2008-10-13T00:00:00Z","timestamp":1223856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1038\/bmt.2008.324","type":"journal-article","created":{"date-parts":[[2008,10,13]],"date-time":"2008-10-13T10:49:49Z","timestamp":1223894989000},"page":"339-343","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Alefacept treatment for refractory chronic extensive GVHD"],"prefix":"10.1038","volume":"43","author":[{"given":"M Y","family":"Shapira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Abdul-Hai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I B","family":"Resnick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Bitan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Tsirigotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Aker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Gesundheit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Or","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,13]]},"reference":[{"key":"BFbmt2008324_CR1","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/archderm.139.6.719","volume":"139","author":"M Lebwohl","year":"2003","unstructured":"Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE . An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139: 719\u2013727.","journal-title":"Arch Dermatol"},{"key":"BFbmt2008324_CR2","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1056\/NEJM200107263450403","volume":"345","author":"CN Ellis","year":"2001","unstructured":"Ellis CN, Krueger GG, Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248\u2013255.","journal-title":"N Engl J Med"},{"key":"BFbmt2008324_CR3","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/j.jaad.2006.07.019","volume":"56","author":"JE Graves","year":"2007","unstructured":"Graves JE, Nunley K, Heffernan MP . Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept. J Am Acad Dermatol 2007; 56: e55\u2013e79.","journal-title":"J Am Acad Dermatol"},{"key":"BFbmt2008324_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1479-5876-5-27","volume":"5","author":"F Chamian","year":"2007","unstructured":"Chamian F, Lin SL, Lee E, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M et al. Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis. J Transl Med 2007; 5: 27\u201333.","journal-title":"J Transl Med"},{"key":"BFbmt2008324_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1365-2249.2007.03380.x","volume":"149","author":"R Larsen","year":"2007","unstructured":"Larsen R, Ryder LP, Svejgaard A, Gniadecki R . Changes in circulating lymphocyte subpopulations following administration of the leucocyte function-associated antigen-3 (LFA-3)\/IgG1 fusion protein alefacept. Clin Exp Immunol 2007; 149: 23\u201330.","journal-title":"Clin Exp Immunol"},{"key":"BFbmt2008324_CR6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1365-2141.2007.06652.x","volume":"138","author":"CJ Fraser","year":"2007","unstructured":"Fraser CJ, Scott Baker K . The management and outcome of chronic graft-versus-host disease. Br J Haematol 2007; 138: 131\u2013145.","journal-title":"Br J Haematol"},{"key":"BFbmt2008324_CR7","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/sj.bmt.1705185","volume":"36","author":"MY Shapira","year":"2005","unstructured":"Shapira MY, Resnick IB, Bitan M, Ackerstein A, Tsirigotis P, Gesundheit B et al. Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report. Bone Marrow Transplant 2005; 36: 1097\u20131101.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2008324_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/09546630601121045","volume":"18","author":"AA Toor","year":"2007","unstructured":"Toor AA, Stiff PJ, Nickoloff BJ, Rodriguez T, Klein JL, Gordon KB . Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity. J Dermatolog Treat 2007; 18: 13\u201318.","journal-title":"J Dermatolog Treat"},{"key":"BFbmt2008324_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.bbmt.2006.01.008","volume":"12","author":"SZ Pavletic","year":"2006","unstructured":"Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006; 12: 252\u2013266.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2008324_CR10","first-page":"273","volume":"17","author":"T Pugatsch","year":"1996","unstructured":"Pugatsch T, Oppenheim A, Slavin S . Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT. Bone Marrow Transplant 1996; 17: 273\u2013275.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2008324_CR11","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1126\/science.3029872","volume":"235","author":"Y Nakamura","year":"1987","unstructured":"Nakamura Y, Leppert O, O'Connel P, Wolff R, Holm T, Culver M et al. Variable number of tandem repeats (VNTR) markers for human gene mapping. Science 1987; 235: 1616\u20131622.","journal-title":"Science"},{"key":"BFbmt2008324_CR12","first-page":"69","volume":"5","author":"K Atkinson","year":"1990","unstructured":"Atkinson K . Chronic graft-versus-host disease. Bone Marrow Transplant 1990; 5: 69\u201382.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2008324_CR13","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1182\/blood.V91.10.3637","volume":"91","author":"HJ Deeg","year":"1998","unstructured":"Deeg HJ, Leisenring W, Storb R, Nims J, Flowers ME, Witherspoon RP et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood 1998; 91: 3637\u20133645.","journal-title":"Blood"},{"key":"BFbmt2008324_CR14","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1182\/blood.V95.12.3683","volume":"95","author":"S Kulkarni","year":"2000","unstructured":"Kulkarni S, Powles R, Treleaven J, Riley U, Singhal S, Horton C et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 2000; 95: 3683\u20133686.","journal-title":"Blood"},{"key":"BFbmt2008324_CR15","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1182\/blood.V75.12.2459.2459","volume":"75","author":"K Atkinson","year":"1990","unstructured":"Atkinson K, Horowitz MM, Gale RP, van Bekkum DW, Gluckman E, Good RA et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75: 2459\u20132464.","journal-title":"Blood"},{"key":"BFbmt2008324_CR16","first-page":"455","volume":"13","author":"LA Ochs","year":"1994","unstructured":"Ochs LA, Miller WJ, Filipovich AH, Haake RJ, McGlave PB, Blazar BR et al. Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation. Bone Marrow Transplant 1994; 13: 455\u2013460.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2008324_CR17","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/sj.bmt.1701423","volume":"22","author":"S Carlens","year":"1998","unstructured":"Carlens S, Ringd\u00e9n O, Remberger M, L\u00f6nnqvist B, H\u00e4gglund H, Klaesson S et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant 1998; 22: 755\u2013761.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2008324_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.7326\/0003-4819-119-3-199308010-00005","volume":"119","author":"DI Marks","year":"1993","unstructured":"Marks DI, Cullis JO, Ward KN, Lacey S, Syzdlo R, Hughes TP . Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: a comparison of complications in the first 2 years. Ann Intern Med 1993; 119: 207\u2013214.","journal-title":"Ann Intern Med"},{"key":"BFbmt2008324_CR19","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1200\/JCO.2001.19.16.3685","volume":"19","author":"C Cutler","year":"2001","unstructured":"Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH . Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001; 19: 3685\u20133691.","journal-title":"J Clin Oncol"},{"key":"BFbmt2008324_CR20","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1182\/blood.V98.6.1695","volume":"98","author":"D Przepiorka","year":"2001","unstructured":"Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001; 98: 1695\u20131700.","journal-title":"Blood"},{"key":"BFbmt2008324_CR21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1126\/science.285.5426.412","volume":"285","author":"WD Shlomchik","year":"1999","unstructured":"Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J et al. Prevention of graft-versus-host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412\u2013415.","journal-title":"Science"},{"key":"BFbmt2008324_CR22","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood.V76.8.1464.1464","volume":"76","author":"PJ Martin","year":"1990","unstructured":"Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR et al. A retrospective analysis of therapy for acute graft versus host disease: initial treatment. Blood 1990; 76: 1464\u20131472.","journal-title":"Blood"},{"key":"BFbmt2008324_CR23","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/blood.V75.4.1024.1024","volume":"75","author":"D Weisdorf","year":"1990","unstructured":"Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N et al. Treatment of moderate\/severe acute graft versus host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024\u20131030.","journal-title":"Blood"},{"key":"BFbmt2008324_CR24","first-page":"297","volume":"109","author":"L Chatenoud","year":"2005","unstructured":"Chatenoud L . Monoclonal antibody-based strategies in autoimmunity and transplantation. Methods Mol Med 2005; 109: 297\u2013328.","journal-title":"Methods Mol Med"},{"key":"BFbmt2008324_CR25","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00277-004-0890-7","volume":"83","author":"R Zeiser","year":"2004","unstructured":"Zeiser R, Marks R, Bertz H, Finke J . Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies. Ann Hematol 2004; 83: 551\u2013565.","journal-title":"Ann Hematol"},{"key":"BFbmt2008324_CR26","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.clindermatol.2007.08.012","volume":"25","author":"K Ghoreschi","year":"2007","unstructured":"Ghoreschi K, Weigert C, R\u00f6cken M . Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol 2007; 25: 574\u2013580.","journal-title":"Clin Dermatol"},{"key":"BFbmt2008324_CR27","first-page":"631","volume":"2","author":"SJ Bashir","year":"2001","unstructured":"Bashir SJ, Maibach HI . Alefacept (Biogen). Curr Opin Investig Drugs 2001; 2: 631\u2013634.","journal-title":"Curr Opin Investig Drugs"},{"key":"BFbmt2008324_CR28","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1073\/pnas.0409569102","volume":"102","author":"F Chamian","year":"2005","unstructured":"Chamian F, Lowes MA, Lin SL, Lee E, Kikuchi T, Gilleaudeau P et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci USA 2005; 102: 2075\u20132080.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbmt2008324_CR29","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/eji.200323586","volume":"33","author":"JC Cooper","year":"2003","unstructured":"Cooper JC, Morgan G, Harding S, Subramanyam M, Majeau GR, Moulder K et al. Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells. Eur J Immunol 2003; 33: 666\u2013675.","journal-title":"Eur J Immunol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2008324.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2008324","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2008324.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T11:23:26Z","timestamp":1648034606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2008324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,13]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["BFbmt2008324"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2008.324","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,13]]},"assertion":[{"value":"26 March 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2008","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2008","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2008","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}